Assessment of tumoricidal efficacy and response to treatment with 18F-FDG PET/CT after intraarterial infusion with the antiglycolytic agent 3-bromopyruvate in the VX2 model of liver tumor

Journal of Nuclear Medicine

Volumn 52, Issue 2, 2011, Pages 225-230

  Liapi, Eleni ^a   Geschwind, Jean Francois H ^a   Vali, Mustafa ^a   Khwaja, Afsheen A ^a   Prieto Ventura, Veronica ^a   Buijs, Manon ^a   Vossen, Josephina A ^a   Ganapathy, Shanmugasudaram ^a   Wahl, Richard L ^b,c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

3 bromopyruvate; Hepatology; Interventional; Liver cancer; PET CT; VX2

Indexed keywords

BROMINE DERIVATIVE; BROMOPYRUVIC ACID; FLUORODEOXYGLUCOSE F 18; PYRUVIC ACID DERIVATIVE; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CALCULATION; CATHETER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG UPTAKE; EXPLANT; GLUCOSE METABOLISM; GLYCOLYSIS; HEPATIC ARTERY; HISTOPATHOLOGY; LIVER TUMOR; MALE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RABBIT; TUMOR NECROSIS; TUMOR VOLUME;

ANGIOGRAPHY; ANIMALS; ENZYME INHIBITORS; FLUORODEOXYGLUCOSE F18; IMAGE PROCESSING, COMPUTER-ASSISTED; INFUSIONS, INTRA-ARTERIAL; LIVER; LIVER CIRCULATION; LIVER NEOPLASMS, EXPERIMENTAL; MALE; NEOPLASM TRANSPLANTATION; PHARMACEUTICAL SOLUTIONS; POSITRON-EMISSION TOMOGRAPHY; PYRUVATE DEHYDROGENASE COMPLEX; PYRUVATES; RABBITS; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 79851476201     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.083162     Document Type: Article

References (20)

1. Warburg O. On the origin of cancer cells. Science. 1956;123:309-314.
2. Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell. 2008;13:472-482. (Pubitemid 351766797)
3. Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene. 2006;25:4633-4646. (Pubitemid 44187614)
4. Kondoh H. Cellular life span and the Warburg effect. Exp Cell Res. 2008;314: 1923-1928.
5. Kelloff GJ, Hoffman JM, Johnson B, et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res. 2005;11:2785-2808. (Pubitemid 40525178)
6. 18F-2-deoxy-2-fluoro-D-glucose uptake into human tumor xenografts: feasibility studies for cancer imaging with positron-emission tomography. Cancer. 1991;67: 1544-1550.
7. Avril NE, Weber WA. Monitoring response to treatment in patients utilizing PET. Radiol Clin North Am. 2005;43:189-204. (Pubitemid 40326568)
8. Geschwind J-FH, Ko YH, Torbenson MS, Magee C, Pedersen PL. Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production. Cancer Res. 2002;62:3909-3913. (Pubitemid 34791050)
9. Vali M, Liapi E, Kowalski J, et al. Intraarterial therapy with a new potent inhibitor of tumor metabolism (3-bromopyruvate): identification of therapeutic dose and method of injection in an animal model of liver cancer. J Vasc Interv Radiol. 2007;18:95-101. (Pubitemid 46628943)
10. Tatsumi M, Nakamoto Y, Traughber B, Marshall LT, Geschwind JF, Wahl RL. Initial experience in small animal tumor imaging with a clinical positron emission tomography/computed tomography scanner using 2-[F-18]fluoro-2-deoxy-D- glucose. Cancer Res. 2003;63:6252-6257. (Pubitemid 37255171)
11. Vali M, Vossen JA, Buijs M, et al. Targeting of VX2 rabbit liver tumor by selective delivery of 3-bromopyruvate: a biodistribution and survival study. J Pharmacol Exp Ther. 2008;327:32-37.
12. Geschwind JF, Georgiades CS, Ko YH, Pedersen PL. Recently elucidated energy catabolism pathways provide opportunities for novel treatments in hepatocellular carcinoma. Expert Rev Anticancer Ther. 2004;4:449-457. (Pubitemid 38745116)
13. Xu R-h, Pelicano H, Zhou Y, et al. Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res. 2005;65:613-621.
14. Oya N, Nagata Y, Tamaki N, et al. FDG-PET evaluation of therapeutic effects on VX2 liver tumor. J Nucl Med. 1996;37:296-302. (Pubitemid 26150907)
15. Kamel IR, Liapi E, Reyes DK, Zahurak M, Bluemke DA, Geschwind JF. Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging. Radiology. 2009;250:466-473.
16. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(suppl 1):122S-150S.
17. Ott K, Fink U, Becker K, et al. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol. 2003;21:4604-4610. (Pubitemid 46594034)
18. Avril N, Sassen S, Schmalfeldt B, et al. Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J Clin Oncol. 2005;23: 7445-7453. (Pubitemid 46291806)
19. Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol. 1993;11:2101-2111. (Pubitemid 23332245)
20. Boehm T, Malich A, Goldberg SN, et al. Radio-frequency tumor ablation: internally cooled electrode versus saline-enhanced technique in an aggressive rabbit tumor model. Radiology. 2002;222:805-813. (Pubitemid 34215234)